Simon Dingemans, Chief Financial Officer discusses the methodology GSK will use for its core earnings reporting to begin with effect from Q1 2012.
Abbas Hussain, President, Emerging Markets & Asia Pacific gave a presentation at the Credit Suisse Asia Healthcare Conference in Hong Kong. Abbas provided an overview of GSK's emerging markets strategy.
Deirdre Connelly, President, North America Pharmaceuticals, gave a presentation at the 2011 Annual Credit Suisse Healthcare Conference in Phoenix, AZ on 10 November. The presentation was attended by institutional investors and portfolio managers. Deirdre provided an overview of GSK’s US Pharmaceuticals business.
Moncef Slaoui, Chairman R&D, discussed the progress GSK has made in increasing the productivity of our R&D organisation during a 'fireside chat' question and answer session at the Morgan Stanley Global Healthcare Conference in NYC on 13 September.
Adrian Rawcliffe, SVP Finance North American Pharmaceuticals, presented at the Bernstein Pharma Conference: “Pharmaceutical R&D Productivity: Diagnosing the Problem & Searching for Solutions” in New York City. The conference was attended by over 100 investors. Ad discussed GSK’s R&D Strategy and its Focus on Return on Investment.
Martin Andrews, SVP – Global Vaccines Centre of Excellence, GSK Biologicals, gave a presentation on GSK’s vaccines business at Citi’s Seminar in London on Vaccines in Emerging Markets.
GSK CEO Andrew Witty presented at the United States Department of State symposium, “The Role of Innovation in Addressing Global Health”. In his address, which was convened to discuss advances and ways of working together to overcome diseases of the developing world, Andrew expanded upon GlaxoSmithKline’s commitments in this area.
Abbas Hussain, President, Emerging Markets, gave a presentation to a small group of investors, where he provided an overview of GSK's emerging markets strategy.
Patrick Vallance, SVP – Medicines Discovery and Development, gave a presentation at the Cowen and Company 31st Annual Health Care Conference in Boston. Patrick provided an overview of GSK’s R&D Strategy and its Focus on Return on Investment.
Deirdre Connelly, President, North American Pharmaceuticals, addressed the CED Biotech/Life Science Conference in Raleigh, Durham, on 21 February 2011.
David Redfern, GSK Chief Strategy Officer, was one of the two keynote speakers at The Economist Pharma Summit Reinventing Pharma for a New Generation on 10 February 2011 in London. He outlined GSK’s strategic priorities, our innovative approach to pricing and the value of our late stage pipeline coupled with our ongoing efforts to drive the effectiveness of R&D.
Deirdre Connelly, President, North American Pharmaceuticals, addressed the 8th annual Center for Business Intelligence (CBI) pharmaceutical compliance conference on 24 January. Deirdre spoke about what the pharmaceutical industry must do to build trust.
David Redfern, Chief Strategy Officer at GlaxoSmithKline, gave a presentation at the 29th Annual JP Morgan Healthcare Conference in San Francisco. David provided an overview of the progress being made in implementing GSK’s strategy.